CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Drugs.com New Drug Applications
Original article

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

BLA FilingRP1Positive
AI Analysis

Summary

Replimune announced FDA acceptance of a resubmitted Biologics License Application for RP1, an oncolytic immunotherapy candidate for advanced melanoma.

Outcome Details

FDA accepted Biologics License Application resubmission

Importance:7/10
Sentiment:
0.70
FDABLAOncolytic ImmunotherapyMelanomaRegulatory
Related Companies
$REPL

Read the original article

Published by Drugs.com New Drug Applications on June 26, 2026 9:06 PM

Read Original